Analyst IMS Investment Management Services Ltd. Invests $66.05 Million in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• IMS Investment Management Services Ltd. opened a new position in Teva, buying 2,116,302 shares worth approximately $66.05 million, representing about 0.18% of Teva and ~1.9% of IMS's portfolio (its sixth-largest holding).
• Company insiders have been net sellers recently: CEO Richard D. Francis sold 442,935 shares for about $14.33 million, and insiders sold 920,901 shares valued at roughly $30.06 million in the past 90 days (insiders own ~0.49%).
• Teva reported better-than-expected Q results (EPS $0.96 vs. $0.65 estimate; revenue $4.71B vs. $4.36B) and gave FY2026 EPS guidance of 2.57–2.77, while analysts raised targets and the consensus price target is $37.67 with a "Moderate Buy" average rating.

Analyst IMS Investment Management Services Ltd. acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,116,302 shares of the company's stock, valued at approximately $66,050,000. Teva Pharmaceutical Industries makes up approximately 1.9% of Analyst IMS Investment Management Services Ltd.'s portfolio, making the stock its 6th largest holding. Analyst IMS Investment Management Services Ltd. owned about 0.18% of Teva Pharmaceutical Industries as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 3.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company's stock valued at $382,000 after acquiring an additional 379 shares in the last quarter. Howard Bailey Securities LLC increased its holdings in Teva Pharmaceutical Industries by 3.5% in the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company's stock worth $292,000 after purchasing an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. raised its position in Teva Pharmaceutical Industries by 1.6% in the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company's stock valued at $645,000 after purchasing an additional 515 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company's stock valued at $81,000 after purchasing an additional 540 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 1.8% during the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company's stock valued at $671,000 after purchasing an additional 588 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 14,150 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the sale, the insider owned 6,774 shares of the company's stock, valued at $214,532.58. This trade represents a 67.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Richard D. Francis sold 442,935 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the sale, the chief executive officer owned 642,099 shares of the company's stock, valued at $20,778,323.64. This represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 920,901 shares of company stock valued at $30,056,789. 0.49% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 16th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday, January 30th. Jefferies Financial Group upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, January 6th. Finally, Scotiabank raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and a consensus target price of $37.67.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $30.11 on Friday. The company has a market capitalization of $34.63 billion, a PE ratio of 25.10, a P/E/G ratio of 10.13 and a beta of 0.76. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The firm has a fifty day simple moving average of $32.15 and a 200 day simple moving average of $27.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business's revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.